TELO
Telomir Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.88
−3.85%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.87
From 52W high−41.28%
Volume234811.00
Market cap$60.18M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$0.87
From 52W high
−41.28%
Volume
234811.00
Market cap
$60.18M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.4x
P/E (TTM)
—
RSI (14)
23.7
MomentumView details →
1D Return
−3.85%
YTD Return
−34.72%
SummaryUpdated Jun 1, 2026
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage biotechnology company founded in 2021 and headquartered in Baltimore, Maryland. The company was formerly known as Metallo Therapies Inc. before changing its name in October 2022. Telomir went public in April 2019 and focuses on developing therapeutic treatments targeting human stem cells and age-related inflammatory conditions. As a pre-clinical company, Telomir has not yet generated revenue and is currently in the research and development phase of bringing its lead drug candidate to market.
Similar companies
Latest newsMore news →
Telomir Pharmaceuticals, Inc. agreed to issue and sell 4,843,300 shares of common stock in a private placement at $1.16 per share for gross proceeds of approximately $5.6 million.30d agoBillionaire entrepreneur and existing significant shareholder John Paul DeJoria increased his investment in Telomir Pharmaceuticals by an additional $1.0 million as part of the company's PIPE financing.30d agoTelomir Pharmaceuticals announced research findings from The Ohio State University College of Veterinary Medicine showing that Telomir-Zn inhibits cell growth in human and canine osteosarcoma models.52d ago